Get Permission Pardeshi, Basalingappa, Bhasale, Kadam, Bhonsle, Sampat, and Valand: Multiple-lesion, non-familial basal cell carcinoma-An interesting oddity


Introduction

Basal cell carcinoma (BCC), known by various synonyms such as ‘Basalioma’, ‘Basal cell epithelioma’, ‘Rodent ulcer’, ‘Jacobs’ ulcer’, was described in 1924.1 Among skin cancers basal cell carcinoma forms the bulk of the primary malignant tumours, which comprises 75 per cent of all skin cancers and it is the most common malignancy among Caucasians.1, 2, 3 Basal cell carcinoma occurs mainly on the sun-exposed areas.1 Rarely it can occur in mucous membrane and skin of palms and soles.4 The incidence of basal cell carcinoma varies from one geographical area to another with incidence being two per 100,000 population in east Asia to 1600 per 100,000 population per year in Queensland, Australia.2 The overall age and sex standardized annual incidence in Minnesota, USA, was reported at 146 per 100 000.5 The incidence of basal cell carcinoma is more common in males over 40 years than in females with mean age at diagnosis being 68 years with male to female ratio being approximately 1.5 to 2:1.6, 7, 8 Individuals with blonde hair, blue eyes have increased risk of developing basal cell carcinoma.5, 7, 9, 10, 11, 12, 13, 14, 15, 16, 17

Basal cell carcinoma is a slow-growing tumor of non-keratinizing cells originating in the basal layer of interfollicular epidermis. 2 It is rarely metastasizing tumour with the rate of metastasis being <0.1 per cent. It generally occurs in skin in sun-exposed areas as a single lesion. The factors contributing to the risk of developing basal cell carcinoma include exposure to arsenic or predisposing conditions like actinic keratosis, Bowen’s Disease, leukoplakia, Erythroplasia of Queyrat, keratoacanthoma, radiation dermatitis, and xeroderma pigmentosum. 3, 4, 5, 6, 7, 18, 19, 20, 21, 9, 22, 8, 10, 11

Basal cell carcinoma especially multiple-lesion basal cell carcinomas occur in association with variety of heredofamilial conditions such as nevoid basal cell carcinoma syndrome (Gorlin’s or Gorlin-Goltz syndrome), 1, 2, 3, 4, 5, 6, 7, 18, 19, 20, 21, 9, 22, 8, 10, 11, 12, 13, 14 Bazex syndrome, Rombo syndrome, and unilateral basal cell nevus syndrome.9 The case being presented here is of multiple-lesion, non-Gorlin syndromic BCC associated with seborrheic keratosis.

Case Report

A 65 year-old male, a farmer by occupation, presented with history of swellings over left cheek just below eyelid and over the forehead. On examination, growth over left cheek was slightly polypoidal and pedunculated. The swelling over the forehead was sessile and globular. The growth over left cheek was clinically diagnosed provisionally as? BCC and the swelling over the forehead region was clinically diagnosed as lipoma. Additionally, the patient also Had multiple, slightly raised macules over the face around the nasolabial fold and Cheek region, which were clinically diagnosed as lesions of Seborrheic keratosis.

The histopathology section of the tertiary care hospital received two specimens in two separate containers labelled separately denoting as swelling over the cheek and forehead, respectively.

Gross examination

On gross examination, the growth over the left cheek was polypoidal in nature and measured 3x2x1 cm in size. Cut section of the growth was grey white with focal areas of hemorrhage. The swelling over forehead was skin-colored, and globular in morphology, soft to firm in consistency, and measured 2 cm in diameter. Cut section of the swelling revealed diffusely yellowish areas. Representative tissue sections were submitted for processing. Tissue sections were processed as per the standard tissue processing method and stained with Hematoxylin and Eosin.

Figure 1

Gross photograph of cut section of lesion over forehead, showing diffusely yellowish areas

https://s3-us-west-2.amazonaws.com/typeset-prod-media-server/ab2255ab-6bcc-428d-a0ed-734c16ac4f83image1.png

Microscopic examination

Sections from the polypoidal growth and swelling over the left cheek region showed epidermis lined by keratinizing stratified squamous epithelium with the subjacent dermis showing multiple discrete nests and sheets of cells separated by fibrous septa. At places, the neoplastic cells form nodular aggregates and cell nests with microcystic areas. The dermis showed a tumor arranged in nodular and focal micro cystic pattern composed of basaloid cells with nuclear palisading at the periphery and surrounding stromal retraction.

Sections from the forehead swelling showed nodular aggregates, islands and sheets of basaloid cells rimmed at the periphery by neat arrangement of cells with nuclear palisading. In some areas the nodular aggregates were interspersed by hyalinised collagen bundles giving an appearance of cribriform pattern. Also noted were nests and sheets of cells separated by deeply eosinophilic basement membrane like material. With above histopathological findings a diagnosis of Basal cell carcinoma with focal trichoepitheliomatous differentiation was made. The patient was further referred to higher center for additional investigations for categorization of Basal cell carcinoma. However, patient was lost in follow up.

Figure 2

Photo micrograph showing basaloid cells with nuclear palisading in periphery and surrounding stromal retraction (H and E, 10x)

https://s3-us-west-2.amazonaws.com/typeset-prod-media-server/ab2255ab-6bcc-428d-a0ed-734c16ac4f83image2.png
Figure 3

Photo micrograph showing basaloid cells with nuclear palisading in periphery and surrounding stromal retraction, (H and E, 40x)

https://s3-us-west-2.amazonaws.com/typeset-prod-media-server/ab2255ab-6bcc-428d-a0ed-734c16ac4f83image3.png
Figure 4

Photo micrograph showing aggregates of basaloid cells separated by delicate hyalinised stroma (H and E, 10x)

https://s3-us-west-2.amazonaws.com/typeset-prod-media-server/ab2255ab-6bcc-428d-a0ed-734c16ac4f83image4.png
Figure 5

Photo micrograph showing aggregates of basaloid cells separated by delicate hyalinised stroma (H and E, 40x)

https://s3-us-west-2.amazonaws.com/typeset-prod-media-server/ab2255ab-6bcc-428d-a0ed-734c16ac4f83image5.png
Figure 6

Photo micrograph showing nests and sheets of cells separated by deeply eosinophilic basement membrane like material (H and E, 40x)

https://s3-us-west-2.amazonaws.com/typeset-prod-media-server/ab2255ab-6bcc-428d-a0ed-734c16ac4f83image6.png

Discussion

Basal cell carcinoma is the commonest cancer, which can occur as a single lesion on the face and neck. Although multiple-lesion basal cell carcinoma is not common, 36-50 percent cases of basal cell carcinoma have an increased risk of developing additional BCC after the first lesion within 5 years. 7, 8 The recurrence rate of BCC is variable; when the tumor is completely excised, the recurrence rate is between 5 per cent and 14 per cent. 18

Basal cell carcinoma can be classified in different ways. One of the classifications categorizes BCC into sporadic (nonsyndromic) and syndromic (hereditary) forms. 2, 14 In the sporadic group of basal cell carcinoma, individuals having BCC do not have any genodermatosis which make them predisposed to get cutaneous malignant tumours. In the second group (syndromic group), individuals are affected with genetic skin disorders (Grolin-Goltz syndrome, Bazex syndrome, xeroderma pigmentosum) which makes them susceptible to develop BCC at an early age. As studied widely, one of the striking features of BCC is its variation in its presentation in sites, number of lesions and its accrual or occurrence of number of tumors per year from the first presentation. 2, 14, 15, 16, 17

Another classification proposed by Ramachandran et al 15 is based on the number of lesions at presentation. It categorizes BCC into single presentation phenotype (SPP) or multiple presentation phenotypes (MPP). 15, 16, 17

SPP can be further subdivided into categories of SPP- one and SPP-more. SPP-one comprises patients with only a single BCC lesion at first presentation with no additional lesions. SPP-more group included patients with only one primary BCC lesion at first presentation but the development of additional single lesions during the follow-up period. MPP was subdivided into MPP-cluster initially and MPP-cluster later. A cluster was defined as the presence of two or more new primary BCC lesions at the same locality. MPP-cluster initial includes patients who present with a cluster of BCC lesions at first presentation but may or may not develop additional BCC during follow-up. MPP-cluster-later comprises patients who had only 1-primary BCC lesion at the first presentation but developed a cluster at a subsequent presentation. Although this classification can be adapted, it had limitations as the development of BCC lesions is a dynamic process over a long period with changes in appropriate categories. Additionally, patients with a single lesion may die before adequate follow-up. 15

The risk factors involved in development of BCC include sensitization of skin by photosensitizing medications such as tetracycline, thiazide diuretics, non-steroidal anti-inflammatory drugs (NSAIDs), retinoid and antimicrobial agents such as tetracycline, which cause phototoxic or photo allergic reactions when exposed to ultraviolet (UV) light, which leads to predisposition of skin to UV-induced damage. The use of anti-microbial agents, particularly tetracycline for the treatment of acne in adolescence along with increased UV-exposure during this active age-group is known to be associated with increased risk of BCC in adults. 2, 6 Of the various risk factors, UV light is a major risk factor triggering mutations in tumor suppressor genes. Ionizing radiation, arsenic, and polyaromatic hydrocarbons play an important role in causing mutation in regulatory genes and alteration in immune surveillance. 6 UV-induced mutations in p53 such as C-C and T-T nucleotide bases in pyrimidine sites are demonstrated to occur in up to 60 per cent of BCC cases. Despite BCC having low metastatic potential, it is aggressive locally and tends to grow and infiltrate in tissues with a path of least resistance. 6 BCC usually metastases to the lung, lymph nodes, esophagus, oral cavity, and skin. Clinical variants of BCC are superficial, nodular, morphea form pigmented, fibro-epithelioma of Pinkus, and cystic BCC. Histological subtypes of BCC include superficial, nodular, micronodular, and infiltrative BCC. 14

The fundamental genetic alterations involved in predisposition to BCC development, especially of multiple tumor development, are not yet clearly understood, but the changed genetic background greatly modulates response of skin to ultraviolent radiation [UVR]. The quintessential effectiveness of DNA reparative mechanisms definitely modifies the entire pathogenetic mechanism of BCC carcinogenesis. Over the years reduced DNA repair capacity (DRC) to repair UVR-induced DNA damage is proven as an independent risk factor for the development of BCC. 2, 5 It is found that the DRC is significantly lower in patients suffering from BCC compared with control subjects, irrespective of biological behavior of the tumour, however it is curious to note that the same is seen among individuals having more than one BCC lesion. Most other studies point to the fact that there may be an effect of genetic alterations in a variety of molecular markers such as carcinogen-metabolizing enzymes, cell-signaling proteins on individuals becoming susceptible BCC. 5, 15, 16, 17 Thus, various studies have demonstrated a close link between glutathione S-transferase, reduced nicotinamide adenine dinucleotide NAD, quinone oxidoreductase; cytochrome P450, vitamin D receptor, tumour necrosis factor alpha, and the protein patched homolog (PTCH) gene polymorphisms and the development of BCC, and the rate of development of BCC in respect to their number and accrual of lesions in individuals affected with BCC. 23, 15, 16, 17, 24

One of the genetic pathways responsible for development of multi-lesion BCC is Nevoid basal cell carcinoma syndrome, an autosomal dominant disorder that is characterized by multiple BCCs, broad nasal root, borderline intelligence, jaw cysts, palmar pits, bilamellar calcification of falx cerebri, and multiple skeletal abnormalities in addition to hundreds of BCC. 21, 9, 22, 8, 10, 11, 12, 13, 14, 23, 15, 16, 17 The gene involved is located on chromosome 9q22.3. known as Patched gene or PTCH gene, it is a tumour suppressor gene, and in normal individuals it inhibits signal transduction in downward genes. In individuals with BCC, mutations in the gene lead to suppression of PTCH receptor to which sonic hedgehog (SHH) binds. This removes suppression of Smoothen protein, which acts as proto-oncogene leading to activation of transduction pathway through downward genes. This downward activation of transduction signaling activates various nuclear transduction genes. This is the molecular basis of development of multi-lesion BCC, which forms the basis of targeted therapy by using drugs such as Vismodegib, which does not have severe adverse drug reactions or long term side effects. The other ways of clinical management of BCC include surgical and non-surgical methods. The surgical methods of treating BCC are excisional surgery, curettage, cautery, cryosurgery and Mohs micrographic surgery, while non-surgical methods include radiotherapy, photodynamic therapy, topical use of fluorouracil and imiquimod. 25, 26

Conclusion

The multiple-lesion basal cell carcinoma case being presented here is one of its own kind in that it is reported from a predominantly tribal region in a patient who does not have family history of heredofamilial conditions that predispose to occurrence of multiple-lesion basal cell carcinoma nor the patient has nevoid basal cell carcinoma syndrome or Gorlin’s syndrome which plays a role in occurrence of multiple-lesion basal cell carcinoma. However, the present case of multiple-lesion basal carcinoma is associated with seborrheic keratosis, the association of which is not known to be associated with multiple-lesion basal cell carcinoma as per the available medical literature.

Individuals with first lesion basal cell carcinoma have tendency to develop multiple basal cell carcinomas in the course of the disease and such first lesion of basal cell carcinoma has to be selected carefully for risk factor profile analysis and close clinical follow-up with periodic screening of any suspicious lesion resembling BCC for early detection of imminent multi-lesion basal carcinoma for early and effective clinical management.

Conflicts of Interest

None.

Source of Funding

None.

References

1 

CM Tilli MA Van Steensel GA Krekels HA Neumann FC Ramaekars Molecular etiology and pathogenesis of BCCBr J Dermatol20051526110824

2 

V Bartos Development of Multiple-Lesion Basal Cell Carcinoma of the Skin: A Comprehensive ReviewSisli Etfal Hastan Tip Bu20195343238

3 

DE Elder D Massi RA Scolyer R Willemze WHO Classification of Skin Tumours, 4th edn.International Agency for Research on Cancer; LyonFrance201826

4 

S Balakrishnan Basal cell carcinoma - PathologyJ Skin Sex Transm Dis20224216470

5 

CSM Wong RC Strange JT Lear Basal cell carcinomaBMJ200332774187948

6 

AG Marzuka SE Book Basal cell carcinoma: pathogenesis, epidemiology, clinical features, diagnosis, histopathology, and managementYale J Biol Med201588216779PMCID

7 

F Lara JR Santamaría LE Garbers Recurrence rate of basal cell carcinoma with positive histopathological margins and related risk factorsAn Bras Dermatol20179215862

8 

V Kiiski E Vries, SC Flohil MJ Bijl A Hofman BHC Stricker Risk factors for single and multiple basal cell carcinomasArch Dermatol2010146884855

9 

TiY Loh, PR Cohen Red Dot Basal Cell Carcinoma: An Unusual Variant of a Common MalignancyJ Drugs Dermato20161556457

10 

SK Ahn HS Lee K Han SH Lee S Lee Multiple BCC associated with keratocanthomaYonsei Med J199233327780

11 

AK Malhotra S Gupta BK Khaitan KK Verma Multiple basal cell carcinomas in xeroderma pigmentosum treated with imiquimod 5% creamPediatr Dermatol200825448891

12 

Y Lü H Zhu W Ye M Zhang D He W Chen A new mutation of PTCH gene in a Chinese family with nevoid basal carcinoma syndromeChin Med J (Engl)2008121211821

13 

Y Alghamdi Skin tags as a presenting sign of basal cell nevus syndrome in three sisters of the same familyAnn Saudi Med20082821324

14 

C Pankaj Non syndromic Multiple BCCInt J Head Neck Surg201011258

15 

S Ramachandran AA Fryer AG Smith JT Lear B Bowers CE Griffith Basal cell carcinomaCancer200089510128

16 

S Ramachandran AA Freyer RC Strange Genetic factors determining cutaneous basal cell carcinoma phenotypeMed Pediatr Oncol200136555963

17 

S Ramachandran AA Freyer A Smith J Lear B Bowers PW Jones Cutaneous basal cell carcinomas: distinct host factors are associated with the development of tumors on the trunk and on the head and neckCancer20019223548

18 

B Nikam A Kshirsagar P Shivhare A Garg Familial Multiple Basal Cell Carcinoma (Gorlin's Syndrome): A Case Report of a Father and SonIndian J Dermatol20135864814

19 

A Agarwal A Raja S Mahalingam K Murhekar Multiple adenoid basal cell carcinoma: An uncommon presentationIndian J Dermatol Venereol Leprol20198543936

20 

R Čeović N Smolković A Pašić K Kostović D Hrsan Multiple basal cell carcinomas of lower legs with stasis dermatitis: a therapeutic challengeActa Dermatovenerol Croat2012203196

21 

R Gorlin Nevoid basal cell carcinoma (Gorlin) syndromeGenet Med20046530910.1097/01.GIM.0000144188.15902.C4

22 

AH Wong AKC Leung B Barankin Sclerosing Basal Cell CarcinomaInt J Clin Med Imaging201524100031510.4172/2376-0249.1000315

23 

JK Robinson Risk of developing another basal cell carcinoma. A 5-year prospective studyCancer198760111820

24 

JT Lear BB Tan AG Smith W Bowers PW Jones AH Heagerty Risk factors for basal cell carcinoma in the UK: case-control study in 806 patientsJ R Soc Med19979073714

25 

FJ Bath -Hextall W Perkin J Bong HC William Interventions for Basal Cell Carcinoma of skinCochrane Database Syst Rev2007241CD00341210.1002/14651858.CD003412

26 

C L Cowey Targeted Therapy for advanced BCC Vismodegib and beyondDermatol Ther (Heidelb)201331173110.1007/s13555-013-0019-9



jats-html.xsl


This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

  • Article highlights
  • Article tables
  • Article images

Article History

Received : 22-08-2023

Accepted : 05-10-2023


View Article

PDF File   Full Text Article


Copyright permission

Get article permission for commercial use

Downlaod

PDF File   XML File   ePub File


Digital Object Identifier (DOI)

Article DOI

https://doi.org/10.18231/j.jdpo.2023.053


Article Metrics






Article Access statistics

Viewed: 421

PDF Downloaded: 156



Medical Abbreviation List